menu
    • menu
    [{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenta Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta Therapeutics \/ GSK"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenta Therapeutics \/ H. Lundbeck AS","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta Therapeutics \/ H. Lundbeck AS"}]

    Find Clinical Drug Pipeline Developments & Deals by Rgenta Therapeutics

    Menu

    Rgenta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RGT-61159

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rgenta Therapeutics Gets IND Clearance for RGT-61159 in ACC and CRC

                            Details : RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB. It is being evaluated for adenoid cystic carcinoma & colorectal cancer.

                            Product Name : RGT-61159

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 07, 2024

                            Lead Product(s) : RGT-61159

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RGT-61159

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rgenta Doses Patients in Trial For MYB-Targeting Drug in ACC And CRC

                            Details : RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB. It is being evaluated for adenoid cystic carcinoma & colorectal cancer.

                            Product Name : RGT-61159

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 10, 2024

                            Lead Product(s) : RGT-61159

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : GSK

                            Deal Size : $546.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Rgenta & GSK Develop RNA Small Molecule Splice Modulators in Strategic Alliance

                            Details : Under the agreement, Rgenta will use its proprietary discovery platform to develop novel oral RNA-targeting small molecule splice modulators against multiple targets nominated by GSK for development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $46.0 million

                            April 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : GSK

                            Deal Size : $546.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Rgenta Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : H. Lundbeck AS

                            Deal Size : $110.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rgenta Therapeutics Enters into a Collaboration with Lundbeck

                            Details : Rgenta will use its novel and integrative discovery platform to identify and optimize RNA-targeting small molecules against high-value targets. Rgenta will grant Lundbeck license of candidate molecules, which will be developed and commercialized by Lundb...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $10.0 million

                            April 08, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : H. Lundbeck AS

                            Deal Size : $110.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth